RecruitingNot Applicable

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

Australia24 participantsStarted 2025-12-01

Plain-language summary

This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men with high-risk BCR PCa but no ADT+/-ARPI experience. * Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment. Exclusion Criteria: • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.

What they're measuring

Number and content of themes and subthemes describing PCa patients' perceptions of the risk of breast-related side effects, including gynaecomastia, from high-risk BCR PCa treatment.

Timeframe: 12 months

Trial details

NCT IDNCT07552922

SponsorSt Vincent's Hospital, Sydney

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-30

View on ClinicalTrials.gov More Prostate Cancer (Adenocarcinoma) trials